Generate Biomedicines Inc (NASDAQ:GENB) Receives Average Recommendation of “Moderate Buy” from Brokerages

Generate Biomedicines Inc (NASDAQ:GENB) has been given a consensus recommendation of “Moderate Buy” by the eight research firms that are currently covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and six have assigned a buy recommendation to the company. The average 12-month price objective among analysts that have issued ratings on the stock in the last year is $25.40.

Several research firms have weighed in on GENB. HC Wainwright lifted their price objective on Generate Biomedicines from $16.00 to $25.00 and gave the company a “buy” rating in a research report on Friday, May 8th. Wall Street Zen cut Generate Biomedicines from a “hold” rating to a “sell” rating in a research note on Saturday, August 8th. Morgan Stanley lifted their price target on Generate Biomedicines from $20.00 to $22.00 and gave the company an “overweight” rating in a research report on Thursday, May 14th. Finally, Weiss Ratings began coverage on Generate Biomedicines in a research note on Tuesday, August 11th. They issued a “sell (d)” rating on the stock.

Generate Biomedicines Stock Down 5.8%

Shares of NASDAQ GENB opened at $15.99 on Friday. Generate Biomedicines has a 12 month low of $11.00 and a 12 month high of $18.18. The company has a market cap of $2.05 billion and a price-to-earnings ratio of -10.06. The stock has a fifty day moving average of $14.89.

Generate Biomedicines (NASDAQ:GENB) last announced its quarterly earnings results on Thursday, August 6th. The company reported ($0.52) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.48) by ($0.04). The company had revenue of $6.31 million for the quarter. Research analysts expect that Generate Biomedicines will post -2.29 EPS for the current year.

Institutional Inflows and Outflows

An institutional investor recently bought a new stake in Generate Biomedicines stock. Susquehanna International Group LLP acquired a new position in shares of Generate Biomedicines Inc (NASDAQ:GENB) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 11,622 shares of the company’s stock, valued at approximately $196,000.

Generate Biomedicines Company Profile

Generate Biomedicines, Inc (NASDAQ: GENB) is a biotechnology company that applies machine learning and generative artificial intelligence to the design and discovery of novel therapeutics. The company develops computational platforms to create and optimize protein sequences and biological molecules with the goal of producing new medicines across a range of modalities. Its core activities center on algorithm-driven design, iterative experimental validation, and the translation of computational outputs into candidate therapeutic molecules.

Generate’s technology combines advanced computational models with high-throughput laboratory methods to accelerate discovery and improve the likelihood of producing viable drug candidates.